capecitabine (xeloda) Report issue

Small molecule Approved FDA Accelerated Approval FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Capecitabine, sold under the brand name Xeloda among others, is a anticancer medication used to treat breast cancer, gastric cancer and colorectal cancer. For breast cancer it is often used together with docetaxel. It is taken by mouth.   Wikipedia

Chemistry

  • SMILES: CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F
  • InChIKey: GAGWJHPBXLXJQN-UORFTKCHSA-N
  • Mol. Mass: 359.35
  • ALogP: 0.76
  • ChEMBL Molecule:
    capecitabine  
More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: Yes

Drug Pricing (per unit)

Australia

$0.1401 - $0.4341

United States

$0.5863 - $44.5047
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

(1-(5-deoxy-beta-d-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester | capacitabine | capecitabin | capecitabina | capecitabine | capecitabine= | capecitabinum | capecitibine | capecytabine | capiibine | captabin | kd018 | pentyl 1-(5-deoxy-beta-d-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate | pentyl [1-(5-deoxy-beta-d-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate | pseudomonas aeruginosa | ro-091978000 | sar439281 | xeloda

Organizations (822)

Research & Development (807)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (17)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (198)

Approved Indications (2)


 

Breast Neoplasms

Colonic Neoplasms

Experimental Indications - Clinical Trial Phases 1-4 (198)


 

Adenocarcinoma (Phase 3)

Adenocarcinoma, Clear Cell (Phase 2)

Adenoma, Islet Cell (Phase 2)

Adrenal Gland Neoplasms (Phase 1)

Adult (Phase 1)

Angiogenesis Modulating Agents (Phase 2)

Anterior Cruciate Ligament Injuries (Phase 2)

Antineoplastic Combined Chemotherapy Protocols (Phase 2)

Anus Diseases (Phase 3)

Anus Neoplasms (Phase 3)

Appendix (Phase 1)

Bevacizumab (Phase 2)

Bile Duct Neoplasms (Phase 3)

Biliary Tract Neoplasms (Phase 3)

Biomarkers (Phase 2)

Brain Neoplasms (Phase 3)

BRCA1 Protein (Phase 1)

Breast (Phase 1/Phase 2)

Breast Carcinoma In Situ (Phase 2)

Breast Diseases (Phase 3)

Breast Neoplasms ()

Breast Neoplasms, Male (Phase 2)

Burkitt Lymphoma (Phase 1)

Capecitabine (Phase 3)

Carcinoma (Phase 3)

Carcinoma, Ductal, Breast (Phase 3)

Carcinoma, Hepatocellular (Phase 2/Phase 3)

Carcinoma, Islet Cell (Phase 2)

Carcinoma, Merkel Cell (Phase 1)

Carcinoma, Neuroendocrine (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Pancreatic Ductal (Phase 2)

Carcinoma, Renal Cell (Phase 3)

Carcinoma, Squamous Cell (Phase 3)

Carcinoma, Transitional Cell (Phase 2)

Carcinoma, Verrucous (Phase 2)

Cetuximab (Phase 2)

Chemoradiotherapy (Phase 3)

Chemotherapy, Adjuvant (Phase 3)

Cholangiocarcinoma (Phase 4)

Circulating Tumor DNA (Phase 2)

Cisplatin (Phase 2)

Cognition Disorders (Phase 3)

Colonic Diseases (Phase 2)

Colonic Neoplasms ()

Colorectal Neoplasms (Phase 4)

Deficiency Diseases (Phase 2/Phase 3)

Digestive System Diseases (Phase 2)

Digestive System Neoplasms (Phase 3)

Disease-Free Survival (Phase 3)

Disease Progression (Phase 2)

DNA Mismatch Repair (Phase 2)

Drug-Related Side Effects and Adverse Reactions (Phase 3)

Drugs, Investigational (Phase 3)

Drug Therapy (Phase 2)

Drug Therapy, Combination (Phase 2)

Endocrine Gland Neoplasms (Phase 1/Phase 2)

Endocrine System Diseases (Phase 1/Phase 2)

Endometrial Neoplasms (Phase 2)

Epidermal Growth Factor (Phase 2)

Epstein-Barr Virus Infections (Phase 2)

ErbB Receptors (Phase 2)

Esophageal Diseases (Phase 1)

Esophageal Neoplasms (Phase 3)

Esophageal Squamous Cell Carcinoma (Phase 3)

Esophagogastric Junction (Phase 2)

Fallopian Tube Neoplasms (Phase 3)

Gallbladder Neoplasms (Phase 3)

Gastrinoma (Phase 2)

Gastrointestinal Diseases (Phase 2)

Gastrointestinal Neoplasms (Phase 3)

General Surgery (Phase 3)

Genes, erbB-2 (Phase 1)

Genetic Predisposition to Disease (Phase 3)

Geriatrics (Phase 3)

Glioblastoma (Phase 2)

Glioma (Phase 2)

Glucagonoma (Phase 2)

Graft vs Host Disease (Phase 2)

Hamartoma (Phase 3)

Hand Injuries (Phase 3)

Head and Neck Neoplasms (Phase 2)

Histone Deacetylase Inhibitors (Phase 1/Phase 2)

HIV Infections (Phase 2)

Hodgkin Disease (Phase 1)

Hospital Costs (Phase 3)

Hypopharyngeal Neoplasms (Phase 2)

Immune Checkpoint Inhibitors (Phase 2)

Immune System Diseases (Phase 2)

Immunotherapy (Phase 2)

Inflammatory Breast Neoplasms (Phase 2)

Insulinoma (Phase 2)

Intestinal Diseases (Phase 2)

Intestinal Neoplasms (Phase 4)

Intraocular Lymphoma (Phase 1)

Kidney Neoplasms (Phase 2)

Klatskin Tumor (Phase 2)

Lapatinib (Phase 3)

Length of Stay (Phase 3)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Leukemia-Lymphoma, Adult T-Cell (Phase 1)

Leukemia, Myeloid, Acute (Phase 3)

Liver Neoplasms (Phase 3)

Lung Diseases (Phase 1)

Lung Neoplasms (Phase 2)

Lymph Nodes (Phase 2)

Lymphoma (Phase 3)

Lymphoma, AIDS-Related (Phase 1)

Lymphoma, B-Cell, Marginal Zone (Phase 1)

Lymphoma, Follicular (Phase 1)

Lymphoma, Large B-Cell, Diffuse (Phase 1)

Lymphoma, Large-Cell, Anaplastic (Phase 1)

Lymphoma, Large-Cell, Immunoblastic (Phase 1)

Lymphoma, Mantle-Cell (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Lymphoma, Primary Cutaneous Anaplastic Large Cell (Phase 1)

Lymphoma, T-Cell (Phase 1)

Lymphomatoid Granulomatosis (Phase 1)

Maintenance (Phase 3)

Melanoma (Phase 1)

Meningeal Carcinomatosis (Phase 3)

Meninges (Phase 2)

Mesothelioma, Malignant (Phase 2)

Microsatellite Instability (Phase 3)

Molecular Mechanisms of Pharmacological Action (Phase 3)

Molecular Targeted Therapy (Phase 2)

Multiple Endocrine Neoplasia Type 1 (Phase 1)

Multiple Endocrine Neoplasia Type 2a (Phase 1)

Multiple Endocrine Neoplasia Type 2b (Phase 1)

Mutation (Phase 3)

Myelodysplastic Syndromes (Phase 1/Phase 2)

Nasopharyngeal Carcinoma (Phase 3)

Nasopharyngeal Neoplasms (Phase 2)

Neoadjuvant Therapy (Phase 3)

Neoplasm Metastasis (Phase 4)

Neoplasms ()

Neoplasms by Site (Phase 3)

Neoplasms, Glandular and Epithelial (Phase 1/Phase 2)

Neoplasms, Second Primary (Phase 3)

Neoplasms, Squamous Cell (Phase 3)

Neoplasms, Unknown Primary (Phase 2)

Neoplastic Cells, Circulating (Phase 3)

Neuroendocrine Tumors (Phase 4)

Oncogene Proteins (Phase 2)

Organ Preservation (Phase 1/Phase 2)

Ovarian Neoplasms (Phase 3)

Oxaliplatin (Phase 2)

Pain (Phase 3)

Palmar Plate (Phase 1/Phase 2)

Pancreas (Phase 1)

Pancreatic Diseases (Phase 1/Phase 2)

Pancreatic Intraductal Neoplasms (Phase 3)

Pancreatic Neoplasms (Phase 4)

Paresthesia (Phase 3)

Pathology (Phase 3)

Patient Participation (Phase 1)

Peritoneal Neoplasms (Phase 3)

Pheochromocytoma (Phase 1)

Pituitary Neoplasms (Phase 2)

Progression-Free Survival (Phase 2)

Prostatic Neoplasms (Phase 2)

Prostatic Neoplasms, Castration-Resistant (Phase 2)

Proto-Oncogene Proteins B-raf (Phase 2)

Pseudomyxoma Peritonei (Phase 2)

Purpura, Thrombocytopenic (Phase 4)

Quality of Life (Phase 3)

Radiation (Phase 3)

Radiation Oncology (Phase 3)

Radiotherapy (Phase 2/Phase 3)

ras Proteins (Phase 3)

Receptors, Fibroblast Growth Factor (Phase 2)

Rectal Diseases (Phase 2)

Rectal Neoplasms (Phase 4)

Recurrence (Phase 3)

Risk Factors (Phase 3)

Salivary Gland Neoplasms (Phase 2)

Sarcoma (Phase 2)

Self Efficacy (Phase 2)

Sezary Syndrome (Phase 1)

Skin Diseases (Phase 3)

Skin Neoplasms (Phase 2)

Small Cell Lung Carcinoma (Phase 2/Phase 3)

Somatostatinoma (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 3)

Stomach Diseases (Phase 3)

Stomach Neoplasms (Phase 4)

Survival (Phase 3)

Temozolomide (Phase 2)

Thymoma (Phase 1)

Thyroid Neoplasms (Phase 1/Phase 2)

Transplantation (Phase 1)

Triple Negative Breast Neoplasms (Phase 3)

Urinary Bladder Neoplasms (Phase 3)

Uterine Cervical Neoplasms (Phase 2)

Uterine Diseases (Phase 1/Phase 2)

Vaginal Neoplasms (Phase 1)

Waldenstrom Macroglobulinemia (Phase 1)

Zollinger-Ellison Syndrome (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 1688
  • # of Trial Organizations: 807

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue